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Edited by Jesus AvilaAbstract The mechanisms that underlie axon formation are
still poorly understood. GSK3 has been recently implicated in
establishing the axon and in its elongation. We have used four
diﬀerent GSK3 inhibitors to determine the role of GSK3 activity
in hippocampal neurons at diﬀerent periods of time. Inhibition of
GSK3 activity impairs axon formation. The ‘‘critical period’’ of
this activity of GSK3 is at least the ﬁrst 24 h since afterwards the
inhibition of GSK3 does not compromise the process of elonga-
tion, although it exacerbates axon branching. Moreover, inter-
ference RNAs impeding the expression of the GSK3 alpha or
beta isoforms in hippocampal neurons prevents an axon from
forming.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neuronal polarization is a complex process that requires the
morphological and functional diﬀerentiation of a somatoden-
dritic and an axonal domain. The formation and outgrowth
of the axon is one of the ﬁrst events in developing neuronal
polarity [1–3]. The morphological diﬀerentiation of cultured
hippocampal neurons is produced when one of the neurites
(Stage 2) becomes diﬀerentiated from the others and it grows
faster to form the axon (Stage 3) [4,5]. The actin microﬁla-
ments and microtubule dynamics strongly inﬂuence the selec-
tion of one neurite as an axon [6–9]. The ensuing
polarization and extension of the chosen neurite (the axon)
may be controlled by the selective distribution of proteins such
as Par-3, Par-6, APC, aPKC and Rap1b [10,11]. Finally, the
mature axon is characterized by the selective localization of
structural or functional proteins into speciﬁc domains like
the axon initial segment (e.g. sodium channels [12]), conferring
the neuron with its functional polarity.
The signals that underlie the decision of axon speciﬁcation
and outgrowth are still poorly understood and only recently
has it been demonstrated that a signaling pathway controlled
by PI3K may determine the appearance of an axon [10]. In-
deed, the integrity and morphology of an axon may be re-
versed by inhibiting PI3K [13]. Hence, the hypothesis
currently accepted is that many extracellular signals trigger a
signaling cascade through PI3K, which regulates the dynamics*Corresponding author. Fax: +34 91 497 4799.
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doi:10.1016/j.febslet.2007.03.018of the actin and microtubule cytoskeleton. Downstream of the
PI3-kinase, some elements have been described that may either
control actin polymerization, such as Cdc42, or that inﬂuence
MT dynamics such as Glycogen synthase kinase 3 (GSK3).
GSK3 is an ubiquitously distributed serine threonine kinase
encoded by two diﬀerent genes, alpha (a) and beta (b) [14,15].
Moreover, these genes encode a set of one alpha (a) and two
beta (b1 and b2) splice variants [16,17]. GSK3 may be regu-
lated by multiple mechanisms and its basal activity subjected
to activation or inhibition [18–20]. The importance of this
can be seen by the correlation of neuropathological processes
such as AD or Ischemia with the deregulation of GSK3 [21].
In turn, GSK3 regulates microtubule growth and stability,
phosphorylating many microtubule associated proteins such
as tau, MAP1b and CRMP-2 or APC. Mutations or the ab-
sence of these proteins modiﬁes the formation and growth of
the axon. GSK3 phosphorylation of microtubule associated
proteins such as MAP1B and tau appears to reduce their bind-
ing to microtubules, therefore maintaining a population of
dynamically unstable microtubules [22]. Thus, GSK3 phos-
phorylation can render the microtubules more dynamic, favor-
ing axon growth and supporting the idea that GSK3 activity is
essential for axon outgrowth [23–27]. Accordingly, the
MAP1B mutant mouse displays retarded axon outgrowth
[28,29]. Hence, it seems that the establishment and outgrowth
of the axon depends on the temporal and spatial regulation of
GSK3 activity [26].
Contrasting results have been observed when GSK3 is inhib-
ited pharmacologically. Thus, Jiang et al. [30] proposed that
GSK3 inhibition induces multiple axon formation in neurons
6 days in vitro (DIV). In contrast, Shi et al. [31] had already
proposed that inhibition of GSK3 during the ﬁrst 2 DIV abol-
ishes axon formation.
In the present work, we demonstrate that GSK3 activity is
necessary for axon outgrowth. Both GSK3 isoforms are local-
ized at the axon growth cone and their inactivation over 6 DIV
abolish axon formation. However, inhibition of GSK3 after
the axon has started to grow produces a substantial branching
in the axon. Moreover, suppression of only GSK3a or only
GSK3b using interference RNAs show that axon formation re-
quires both GSK3a and GSK3b.2. Materials and methods
2.1. Plasmids, inhibitors and antibodies
The GSK3 inhibitors used in this study were lithium chloride (Sig-
ma), SB-216763, SB-415286 (Tocris) and AR-A014418 (kindly sup-
plied by Dr. R. Bath from AstraZeneca) all of which were dissolved
in DMSO.blished by Elsevier B.V. All rights reserved.
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U6-GSK3bHP1, were a generous gift from Dr. D.L. Turner (Univer-
sity of Michigan). The primary antibodies used were Tau-1 (1:1000,
Sigma), SMI-31 (1:500, Aﬃnity), 514 (1:400; polyclonal anti-MAP2,
previously published [32]), PanNaCh (1:50, Sigma), tyrosinated tubulin
(1:400, Sigma), fPKC and APC (1:1000, Santa Cruz Biotechnology),
GSK3b and GSK3a (1:200, Santa Cruz Biothecnology) and GSK3a/
b (Biosource; 1:1000).
2.2. Cell culture
Primary hippocampal neurons were prepared from E17 mice. Hip-
pocampi were digested with 0.25% trypsin, dissociated with a ﬁre pol-
ished Pasteur pipette and plated on poly-L-lysine coated plates (1 mg/
ml) at a density of 10000 cells/cm2. After 2 h, the plating medium
(MEM, 10% horse serum, glucose 0.6%) was replaced with Neurobasal
medium supplemented with B27 and Glutamax-I. GSK3 inhibitors
were added in fresh medium 4 h after plating and replaced every 3 days
where necessary. Neuronal transfection was carried out 4 hours after
plating using lipofectamine 2000 (9 ll, Invitrogen), 3 lg of U6-
GSK3aHP1 or U6-GSK3bHP1 shRNA vectors and 1 lg of pEGFP-
N1. The transfection mix was removed after 2 h and the neurons were
washed and maintained for 3 DIV.
2.3. Immunoﬂuorescence
Immunocytochemistry was performed on cultures of diﬀerent ages
following ﬁxation of the neurons in 4% paraformaldehyde for
20 min. Non-speciﬁc binding was blocked with 0.22% gelatin and
0.1% Triton X-100 in 0.1 M phosphate buﬀer (PB). The cells were then
incubated with primary antibodies for 1 h at room temperature,
washed and incubated with Alexa conjugated secondary antibodies
(1:1000). The coverslips were ﬁnally mounted using Fluoromount G
(Southern Biotech) and images were obtained on a Zeiss confocal
microscope. The results represent the means and S.D. of at least three
independent experiments.
2.4. Western blot analysis
Hippocampal neurons were cultured for 2 days in poli-lysine coated
plates at a density of 60000/cm2, washed with PBS at 4 C and homog-
enized in lysis buﬀer containing 100 mM NaCl, 20 mM Tris, pH 7.4,
1 mM EDTA, 1% TX-100, 100 lM phenylmethylsulfonyl ﬂuoride,
1 lg/ml aprotinin and leupeptin (Sigma), and 100 lM ortho-vanadate.
The extracts were cleared by centrifugation at 15000 rpm for 15 min.
The proteins of cell extracts were separated by 10% SDS–PAGE, trans-
ferred to nitrocellulose and the membrane was blocked with 5%
non-fat milk before being probed with anti-actin, anti-tau1 and anti-
PHF-1.Fig. 1. Inhibition of GSK3 avoids axon formation in cultured
hippocampal neurons. (A) After plating, hippocampal neurons were
treated with the GSK3 inhibitor AR-A014418 and maintained in
culture. After 2 DIV neurons were ﬁxed and stained anti-tyrosinated-
tubulin and phalloidin-Alexa 594. Neurons treated with DMSO
developed axons that could be identiﬁed morphologically. In contrast,
neurons treated for 48 h with 20 lM AR-A014418 were unable to
develop axons. Scale Bar = 100 lm. (B) Dose-dependence eﬀect of
diﬀerent GSK3 inhibitors in axon formation. (C) Percentage ± S.D. of
neurons developing an axon after 48 h in the presence of GSK3 and
PI3kinase inhibitors (n = 10). (D) Hippocampal neurons treated with
GSK3 inhibitors for 6 DIV after plating do not form axons as shown
by the absence of a tau-1 or SMI-31 positive processes. The
somatodendritic compartment is identiﬁed by MAP2 staining. Scale
Bar = 100 lm.3. Results
3.1. Inhibition of GSK3 activity impairs axon formation in
cultured hippocampal neurons
To test the role of GSK3 activity on axon formation in hip-
pocampal neurons, we examined the eﬀect of diﬀerent inhibi-
tors of this kinase including lithium chloride, SB-415286,
SB-216763 and AR-A014418. The AR-A014418 does not sig-
niﬁcantly inhibit 27 other kinases demonstrating high speciﬁc-
ity for GSK3 [33]. Hippocampal neurons were exposed to the
inhibitors for 2 DIV or 6 DIV. The overall morphology of the
neurons was examined using an antibody against tubulin,
while the dendrites were identiﬁed by MAP2 staining. Axons
were deﬁned by their length as well as their recognition by
the axonal markers SMI-31 (MAP1B-P) and tau-1 (Fig. 1).
Under control conditions, neurons developed one axon and
several dendrites (86 ± 4%, n = 10). In contrast, an axon only
developed in a small percentage of the neurons that were ex-
posed to the GSK3 inhibitors for 2DIV (lithium chloride
10 mM, 7.28 ± 5.91%; SB-415286 50 lM, 18.5 ± 10.08%; AR-
014418 20 lM, 12.44 ± 7.28%; n = 10; Fig. 1C and Supplemen-tary Fig. 1S). This inhibition of axon formation mediated by
the inhibitors of GSK3 was also dose-dependent (Fig. 1B).
As a positive control of axon formation inhibition, we inhib-
ited, in parallel, PI3K using LY294002 (50 lM). Under these
conditions, only 13.82 ± 3.71% neurons developed an axon
(n = 10; Fig. 1C).
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niﬁcant percentage of neurons were unable to develop an axon
(30 ± 12%), while 12 ± 9% only developed a short axon, com-
pared to control neurons (89.9 ± 5%, single axon). The eﬀect of
the inhibitors was speciﬁc to axon formation since inhibition of
GSK3 did not aﬀect the development of MAP2 positive den-
drites, which did not diﬀered signiﬁcantly in length, morphol-
ogy and number of dendrites from untreated neurons
(Fig. 1A,D).
The inhibition of GSK3 was conﬁrmed by Western blotting.
Following GSK3 inhibition, there was a shift in Tau-1 mobil-
ity towards a lower molecular weight, at the same time as the
PHF-1 almost completely disappeared. These changes reﬂected
the failure of GSK3 to phosphorylate these proteins (Supple-
mentary Fig. 2S). The incapacity to detect SMI-31 immunore-
activity also indicated that GSK3 activity had been completely
inhibited (Fig. 1D), as this epitope is dependent on MAP1B
phosphorylation by GSK3 at this neuronal stage.
To determine whether the short neurites extended, when
GSK3 is inhibited, retain the potential to form axons, we re-
moved the inhibitor and analyzed the capacity of neurons to
form an axon under these conditions. After exposure to
GSK3 inhibitors for 2 days (Fig. 2B versus A), the neurons
were washed and grown in permissive conditions for a further
24 h (Fig. 2C). Irrespective of the GSK3 inhibitor used, aroundFig. 2. The eﬀect of GSK3 inhibition on axon formation is reversible. (A)
inhibitors form axons identiﬁed by the SMI-31 axonal marker and morphol
with 20 lM AR-A014418 did not develop axons. (C) Neurons treated with
culture without inhibition were able to develop SMI-31 processes (axons). (D
presence of AR-A014418, SB-415286 and Lithium Chloride for 3 DIV (0–72
Scale Bar = 100 lm.75 ± 5 % (n = 3) of the neurons were able to recover from the
inhibition of GSK3 and they grew an axon (Fig. 2C).
3.2. Axon formation requires GSK3 activity during the ﬁrst 24 h
In order to asses the function of GSK-3 in axon establish-
ment or axon elongation, we inhibited GSK3 in cultured hip-
pocampal neurons only the ﬁrst 24 h and let 5 more days in
culture without inhibition. In this condition, most neurons
developed a single axon after 6 DIV (90.4 ± 9%). However,
these axons often presented an unconventional morphology,
they were mostly branched (with multiple secondary and ter-
tiary extensions) and in many cases they were curled (Fig. 3).
To asses the possibility of multiple axons in GSK3 inhibited
hippocampal neurons as proposed [30], we used an antibody
that recognizes the axon initial segment [12] and is not related
with GSK3 activity. The localization of sodium channels in the
axon initial segment [12] permits the number of axons in each
neuron to be clearly ascertained. However, in all cases only one
axon initial segment could be detected (Fig. 3).
In order to determine whether the eﬀect of GSK3 inhibitors
on axon growth was dependent on a speciﬁc ‘‘pharmacological
window’’, we permitted neurons an initial period of neurite
growth and at diﬀerent times thereafter, they were exposed
to the inhibitors of GSK3. As a result, we found that the
inhibition of GSK3 did not reduce axonal elongation whenHippocampal neurons maintained for 3 DIV in the absence of GSK3
ogically using anti-tyrosinated tubulin. (B) Neurons treated for 3 DIV
GSK3 inhibitors for 2 DIV, washed and maintained one more day in
) Percentage ± S.D. of neurons developing an axon in the absence or
h) or only the ﬁrst 2 DIV (0–48 h) in three independent experiments.
Fig. 3. Dual eﬀects of GSK3 inhibition at diﬀerent stages of axon development in hippocampal neurons. Neurons maintained in culture for 6 DIV in
the absence of GSK3 inhibitors (upper row) were able to develop an axon that could be identiﬁed by tau-1, SMI-31 and the axon initial segment
(AIS) marker PanNaCh (green). The somatodendritic domain was identiﬁed by MAP2 staining (red). Neurons treated with AR-A014418 20 lM only
during the ﬁrst day of culture (0–24 h, middle row) developed axons similar to control neurons but curled and ramiﬁed. (Bottom row) Inhibition of
GSK-3 for 5 DIV after the ﬁrst day in culture (24–144 h) did not aﬀect axon formation and resulted in a pronounced axonal branching. In all cases
only one axon per neuron was observed as indicated by the number of axon initial segments (right column). Scale Bar = 100 lm.
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three days under normal culture conditions (Fig. 3 and Supple-
mentary Fig. 3S). In all cases, almost all neurons developed
one axon (82 ± 12%, n = 3), as seen by the presence of only
one axon initial segment. However, the axonal morphology
was not totally wild-type as multiple ramiﬁcations and branch-
ing could be observed (Fig. 3 and Supplementary Fig. 3S).
3.3. GSK3a and GSK3b are localized at the growth cone of
developing axons
The results obtained by inhibition of GSK3 show that GSK3
activity is necessary for axon formation, but also plays a role in
the further axon development. This activity may control the
function of other proteins located in the axon growth cone,
such as APC or fPKC. However, the inhibitors do not discrim-
inate between GSK3 isoforms, alpha and beta. In order to
asses the role of each isoform of GSK3, we immunostained 2
DIV cultured hippocampal neurons with antibodies that rec-
ognize speciﬁcally GSK3a or GSK3b. As shown in Fig. 4,
GSK-3a and GSK-3b are localized in the soma and concen-
trated in the axon growth cone, but not in the growth cone
of other neurites. Moreover, this localization resembles that
of APC and fPKC. When neurons were treated with GSK-3inhibitors, axons did not developed and GSK-3a, GSK-3b,
APC and fPKC stainings were homogeneously distributed in
the neuron without any concentration in growth cones.
3.4. Both GSK3 a and b are necessary for axon establishment
We have shown that the pharmacological inhibition of
GSK3 with diﬀerent compounds prevented the establishment
of a polarized axon and that GSK3 isoforms, alpha and beta
are present in the growth cone of a developing axon. These re-
sults indicate that GSK3a and/or GSK-3beta play a role in
axon formation. However, we cannot conclude if only one or
both GSK3 isoforms are responsible for axon formation. To
extend this analysis further, we have used a genetic approach
to interfere with GSK3 alpha or GSK3 beta expression. We
performed RNA interference experiments with vectors that
speciﬁcally interfere with the expression of GSK3a or GSK3b
[34]. These vectors were ﬁrst tested in N2A cells conﬁrming
that the expression of each isoform was suppressed by about
70% in accordance with earlier results (Fig. 5A). Subsequently,
neurons were transfected with the GSK3a or GSK3b interfer-
ence vectors in combination with a pEGFP-N1 vector, while
hippocampal neurons transfected with pEGFP-N1 alone
served as controls (Fig. 5B). Neurons were maintained in cul-
Fig. 4. GSK3 alpha and GSK3 beta are localized at the axon growth cone. Hippocampal neurons were grown for 48 h in the absence or presence of
the GSK-3 inhibitor AR-A014418. Neurons were immunostained with antibodies against APC, fPKC, GSK3a and GSK3b. Axons were identiﬁed by
tau-1 staining. The images show that all four proteins are concentrated at the axon growth cone in control conditions. In the presence of GSK-3
inhibitor, neurons did not form an axon and all four proteins were distributed homogeneously in the soma and neurites. Scale Bar = 50 lm.
Fig. 5. Suppression of GSK3a or GSK3b expression impairs axon formation. (A) N2A cells were transfected with U6-GSK3aHP1 or U6-
GSK3bHP1 RNA interference vectors and maintained for 3 DIV. Both vectors were able to reduce a 70% the expression of GSK3a or GSK3b,
respectively. (C) These vectors were co-transfected with GFP in hippocampal neurons 4 h after plating. Only 42% of the neurons co-transfected with
GFP and U6-GSK3aHP1 developed axons, and 51% when U6-GSK3bHP1 was transfected. In contrast, 89% of control neurons (B), transfected only
with GFP, were able to develop an axon after 3 DIV. (D, E) Neurons transfected with U6-GSK3aHP1 or U6-GSK3bHP1 were stained with the
axonal marker tau-1 or tyrosinated-tubulin in combination with GFP ﬂuorescence. Neurons transfected with the RNA interference vector do not
present any tau-1 positive process, neither a longer process identiﬁable in the tubulin staining. Scale Bar = 25 lm.
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fully developed in the control neurons, and the expression of
diﬀerent axonal and somatodendritic markers was assessed
(Fig. 5B).
Suppression of GSK3a impaired the establishment of the
axon, and only 42% ± 10% (n = 4) of the GFP positive neurons
formed an axon (Fig. 5C). Similar results were obtained when
GSK3b was suppressed (51 ± 12%, n = 4). Moreover, GSK3bseemed to be more important than GSK3a in the development
of dendrites, since neurons transfected with GSK3a-HP1 inter-
ference RNA developed a more robust dendritic arbor
(Fig. 5D) than those transfected with GSK3b-HP1 (Fig. 5E).
Thus, while it has been proposed that GSK3b is the isoform
that is principally involved in establishing the axon and in its
elongation, the results presented here show that both isoforms
are necessary to establish an axon.
1584 J.J. Garrido et al. / FEBS Letters 581 (2007) 1579–15864. Discussion
The establishment of neuronal polarity and axon outgrowth
is a highly regulated and not well-known phenomenon. One of
the signaling pathways that regulate the axon formation is the
pathway of PI3-kinase. One of the enzymes controlled by PI3-
kinase is GSK3, which is thought to participate in many
pathways that control morphogenesis, synaptogenesis [35] or
survival [36,37]. GSK3 is a widely distributed serine–threonine
kinase encoded by two diﬀerent genes, GSK3a and b [14,15].
Moreover, the developmental proﬁle of GSK3a and b expres-
sion is diﬀerent and speciﬁcally, the expression of the b isoform
is down-regulated after birth.
Our results show that GSK3 activity is necessary in hippo-
campal neurons to establish an axon and maintained inhibition
of GSK3 prevents axon formation. However, inhibition of
GSK3, once the axon has started to elongate, produces axonal
branching. Even more, this is the ﬁrst time showing that the
establishment of an axon requires both GSK3 isoforms,
GSK3a and GSK3b, which are diﬀerentially concentrated
along the axon.4.1. GSK3 in neuronal polarity
Axon outgrowth and elongation is dependent on actin and
microtubule cytoskeleton (MT) dynamics, as well as on the
traﬃcking machinery that transports membrane components
and proteins to the growing axon. The disruption of the actin
cytoskeleton with cytochalasin D can aﬀect the fate of neurites
and it leads to the production of multiple axons [8]. After dis-
rupting the actin cytoskeleton, elongation is achieved through
the polarized growth of microtubules. The dynamics and the
stability of microtubules are regulated by microtubule associ-
ated proteins (MAPs), which in turn are mainly regulated by
phosphorylation. Indeed, the elimination of some of these pro-
teins, such as tau or MAP1B using antisense oligonucleotides
prevents axon initiation and elongation [38]. Accordingly, hip-
pocampal neurons from MAP1B mutant mouse display im-
paired axonogenesis [39].
In general, GSK3 phosphorylates MAPs such as MAP1B or
tau, making microtubules more unstable and dynamic. How-
ever, this phosphorylation appears not to be homogeneous
throughout the axon and for that reason, tau-1 or MAP1B-
SMI31 staining appears in a gradient in this structure. Thus,
the normal growth of an axon appears to require a certain level
of GSK3 activity [26,40,41]. In this sense, our results show that
inhibition of GSK-3 blocks axon formation in hippocampal
neurons, in agreement with previous results [31], without
aﬀecting the growth of other neurites. This inhibition is con-
ﬁrmed by molecular weight shift of tau-1 and the absence of
MAP1B-P (SMI-31) staining in inhibited neurons. Similar re-
sults have been recently published, indicating that inhibition
of GSK-3 with other speciﬁc inhibitor blocks axon growth in
DRG neurons [42]. All these data are in agreement with the
ﬁrst report of Shi et al. [31]. The eﬀect of GSK-3 inhibition that
blocks axon formation and elongation is only observed when
neurons are treated since the ﬁrst day of culture. Treatments
after the ﬁrst 24 h, produces one axon with an extensive
branching. This branching eﬀect may be produce by partial
inhibition of GSK-3. Indeed, a role for GSK3 activity in cargo
delivery by kinesins has been proposed [43,44], and the balance
between the active and inactive state of GSK-3 would decidethe point of cargo delivery and the outgrowth of a ramiﬁcation
in the axon.
This partial inhibition could also aﬀect in diﬀerent ways dif-
ferent substrates of GSK-3 modifying the pattern of growth of
the axon. For example, CRMP2, another microtubule associ-
ated protein that is a substrate of GSK3 [43,44], and overex-
pression of this protein in hippocampal neurons produces
multiple axons [45]. However, there are contradictory results
about how the regulation of CRMP-2 by GSK3 aﬀects axon
outgrowth and elongation. While the expression of a mutation
in the GSK3 phosphorylation site produces multiple axons
[43], transfection of a mutant CRMP-2 in which the site re-
quired to prime GSK3 phosphorylation is altered aﬀects axo-
nal growth [44]. These data highlight the complexity of
CRMP-2 regulation in axon outgrowth and may reﬂect the
complexity of GSK-3 regulation.4.2. What inﬂuence does GSK3 exert on neuronal polarity?
Some controversial data have recently surfaced regarding
the function of GSK3 in establishing an axon. While inhibition
of GSK3 was initially proposed to impair axon formation [31],
it was more recently suggested that such inhibition leads to the
formation of multiple axons [30]. It was argued that the diﬀer-
ence between these two eﬀects could be due to the use of diﬀer-
ent inhibitors and time periods. More recent data, using a
diﬀerent GSK3 inhibitor, and the GSK3 peptide inhibitor,
indicated that the inhibition of GSK3 impaired axonal elonga-
tion of DRG [42].
In this report, we have used four diﬀerent inhibitors and we
have analyzed how these inﬂuence axon formation and elonga-
tion in the period of time between the ﬁrst and sixth day after
plating. One of these inhibitors, AR-A014418, has been tested
against other 27 kinases and it has been demonstrated its spec-
iﬁcity for GSK-3 [33] and our results show that the inhibitory
eﬀect of all inhibitors is dose dependent. In this way, we have
demonstrated that GSK3 activity is essential for a neurite
(Stage 2) to extend as an axon (Stage 3), and consequently
the formation of the axon initial segment (AIS) [12]. Upon re-
lease from inhibition, neurons are able to develop axons and
only one axon, containing one AIS per neuron. Indeed, when
GSK3 is inhibited after the neurons have been cultured for
3, 2 or even 1 day in culture, an axon is speciﬁed and only a
single axon is extended by each neuron.
Our data are in agreement with the data presented by Shi
et al. [31] and Kim et al. [42] and the fact that some results
have pointed the formation of multiple [30,46] may have arisen
due to the use of the Tau-1 antibody which is GSK3 sensitive.
When GSK3 activity is inhibited, tau-1 immunoreactivity aug-
ments and lower molecular weight bands can be detected in
parallel with an increase in somatodendritic tau staining.
Moreover, on occasions a curling and branching of the axon
occurs, which when passing close to the soma and dendrites
can be mistaken as another axon. Alternatively many labs
use other phosphoepitopes to label axons such as MAP1B-
SMI 31. However, in this case no more accurate identiﬁcation
of the axons is facilitated, since SMI-31 is dependent on GSK3
phosphorylation.
Moreover, to avoid any epitope dependent or GSK3 related
eﬀects, we have taken advantage of the fact that certain pro-
teins are speciﬁcally localized in the axon initial segment
(AIS) of mature axons. This axonal domain appears in hippo-
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using antibodies against voltage-gated sodium channels [12].
Thus, number of axons in a neuron can be identiﬁed by the
number of AIS that form.
When we analyzed longer periods of GSK3 inhibition
(6DIV), we found that 30% of neurons still did not extend
an axon, while 10% developed a short and aberrant axon.
Moreover, 48% of neurons extend an axon which we under-
stand as an ‘‘escape’’ phenotype from pharmacological inhibi-
tion. Indeed, when we analyzed the population that developed
an axon in more detail, the processes were initiated from a sin-
gle axonal initial segment. Only a small proportion of the neu-
rons developed multiple axons, which is not unusual as such
circumstances were observed in control cultures (6% in un-
treated neurons versus 10% in neurons in which GSK3 was
inhibited over 6-days). And more important, when inhibition
was withdrawn after three days, a normal phenotype was al-
most completely recovered and 90% of the neurons contained
a single AIS/neuron. This result permits conclude that inde-
pendently of the diﬀerent interpretations given to these neu-
rites as potential multi-axons in GSK3-inhibited neurons,
after withdrawn of inhibition only a single mature and func-
tional axon is generated.
Consequently, our data show that although a certain
amount of GSK3 activity is necessary during the ﬁrst 24 h in
culture for an axon to be established, the subsequent inhibition
after this period does not appear to compromise axonal spec-
iﬁcation. However, the subsequent inhibition of GSK3 activity
aﬀects the ﬁnal phenotype of the axon which is no longer com-
pletely normal, becoming more branched, arched and ramiﬁed
than in normal cultured hippocampal neurons. To a certain ex-
tent, this agrees with data indicating that the inhibition of
GSK3 promotes elongation mediated by neurotrophins in neu-
rons of the peripheral nervous system [26]. All these data and
previous studies [26,40] indicate that a certain amount of
GSK3 activity is essential to specify an axon, and that main-
taining axon extension does not require a major contribution
of GSK3 activity. Finally, we can also conclude that axonal
ramiﬁcation is exacerbated by the inhibition of GSK3.
Most studies of the function of GSK3 in neuronal morphol-
ogy and physiology have focused on the more abundant
GSK3b, although some studies have highlighted a role for
GSK3a in neuronal diseases [47]. Thus, we hypothesize that
axon formation might depend on both isoforms; particularly
since the GSK3 inhibitors used are unable to diﬀerentiate be-
tween the two of them.
We found that both GSK3 isoforms are present in the axon
growth cone and that both are essential for axon speciﬁcation.
Hence, in our experiment with shRNAs, which strongly sup-
press speciﬁcally either GSK3a or GSK3b, any of them is en-
ough to impair axon formation. This was conﬁrmed using two
diﬀerent shRNAs for each isoform.
Thus, we can not rule out the possibility that each isoform
may have a speciﬁc function in neuronal morphogenesis. In
this sense, neurons were the GSK3b isoform was suppressed
were not able to develop or initiate the growth of dendrites
after 3DIV compare to neurons where only the GSK3a iso-
form was suppressed. Indeed, GSK3b plays an essential role
in dendrite initiation and growth [48].
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